145 related articles for article (PubMed ID: 35029045)
1. The anti-C5a antibody vilobelimab efficiently inhibits C5a in patients with severe COVID-19.
Vlaar APJ; Lim EHT; de Bruin S; Rückinger S; Pilz K; Brouwer MC; Guo RF; Heunks LMA; Busch MH; van Paassen P; Riedemann NC; van de Beek D
Clin Transl Sci; 2022 Apr; 15(4):854-858. PubMed ID: 35029045
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic analysis of vilobelimab, anaphylatoxin C5a and antidrug antibodies in PANAMO: a phase 3 study in critically ill, invasively mechanically ventilated COVID-19 patients.
Lim EHT; Vlaar APJ; de Bruin S; Rückinger S; Thielert C; Habel M; Guo R; Burnett BP; Dickinson J; Brouwer MC; Riedemann NC; van de Beek D;
Intensive Care Med Exp; 2023 Jun; 11(1):37. PubMed ID: 37332066
[TBL] [Abstract][Full Text] [Related]
3. Anti-C5a antibody vilobelimab treatment and the effect on biomarkers of inflammation and coagulation in patients with severe COVID-19: a substudy of the phase 2 PANAMO trial.
Lim EHT; Vlaar APJ; Bos LDJ; van Vught LA; Boer AMT; Dujardin RWG; Habel M; Xu Z; Brouwer MC; van de Beek D; de Bruin S;
Respir Res; 2022 Dec; 23(1):375. PubMed ID: 36566174
[TBL] [Abstract][Full Text] [Related]
4. Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial.
Vlaar APJ; de Bruin S; Busch M; Timmermans SAMEG; van Zeggeren IE; Koning R; Ter Horst L; Bulle EB; van Baarle FEHP; van de Poll MCG; Kemper EM; van der Horst ICC; Schultz MJ; Horn J; Paulus F; Bos LD; Wiersinga WJ; Witzenrath M; Rueckinger S; Pilz K; Brouwer MC; Guo RF; Heunks L; van Paassen P; Riedemann NC; van de Beek D
Lancet Rheumatol; 2020 Dec; 2(12):e764-e773. PubMed ID: 33015643
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Vilobelimab (IFX-1), a Novel Monoclonal Anti-C5a Antibody, in Patients With Early Severe Sepsis or Septic Shock-A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase IIa Trial (SCIENS Study).
Bauer M; Weyland A; Marx G; Bloos F; Weber S; Weiler N; Kluge S; Diers A; Simon TP; Lautenschläger I; Gründling M; Jaschinski U; Simon P; Nierhaus A; Moerer O; Reill L; Jörres A; Guo R; Loeffler M; Reinhart K; Riedemann N
Crit Care Explor; 2021 Nov; 3(11):e0577. PubMed ID: 34806021
[TBL] [Abstract][Full Text] [Related]
6. Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Vlaar APJ; Witzenrath M; van Paassen P; Heunks LMA; Mourvillier B; de Bruin S; Lim EHT; Brouwer MC; Tuinman PR; Saraiva JFK; Marx G; Lobo SM; Boldo R; Simon-Campos JA; Cornet AD; Grebenyuk A; Engelbrecht JM; Mukansi M; Jorens PG; Zerbib R; Rückinger S; Pilz K; Guo R; van de Beek D; Riedemann NC;
Lancet Respir Med; 2022 Dec; 10(12):1137-1146. PubMed ID: 36087611
[TBL] [Abstract][Full Text] [Related]
7. Optimizing the use of vilobelimab for the treatment of COVID-19.
McCarthy MW
Expert Opin Biol Ther; 2023; 23(9):877-881. PubMed ID: 37421632
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneity of treatment effect of vilobelimab in COVID-19: a secondary analysis of a randomised controlled trial.
van Amstel RBE; Slim MA; Lim EHT; Rückinger S; Seymour CW; Burnett BP; Bos LDJ; van Vught LA; Riedemann NC; van de Beek D; Vlaar APJ;
Crit Care; 2024 Jun; 28(1):210. PubMed ID: 38943192
[TBL] [Abstract][Full Text] [Related]
9. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
[TBL] [Abstract][Full Text] [Related]
10. Alterations in systemic complement component 3a and 5a levels in patients with cerebral arteriovenous malformations.
Haque R; Hwang BY; Appelboom G; Piazza MA; Guo K; Connolly ES
J Clin Neurosci; 2011 Sep; 18(9):1235-9. PubMed ID: 21742500
[TBL] [Abstract][Full Text] [Related]
11. Detection of native human complement components C3 and C5 and their primary activation peptides C3a and C5a (anaphylatoxic peptides) by ELISAs with monoclonal antibodies.
Klos A; Ihrig V; Messner M; Grabbe J; Bitter-Suermann D
J Immunol Methods; 1988 Jul; 111(2):241-52. PubMed ID: 3260926
[TBL] [Abstract][Full Text] [Related]
12. Plasma clearance of the human C5a anaphylatoxin by binding to leucocyte C5a receptors.
Oppermann M; Götze O
Immunology; 1994 Aug; 82(4):516-21. PubMed ID: 7835913
[TBL] [Abstract][Full Text] [Related]
13. Effect of anaphylatoxin C3a, C5a on the tubular epithelial-myofibroblast transdifferentiation in vitro.
Liu F; Gou R; Huang J; Fu P; Chen F; Fan WX; Huang YQ; Zang L; Wu M; Qiu HY; Wei DP
Chin Med J (Engl); 2011 Dec; 124(23):4039-45. PubMed ID: 22340339
[TBL] [Abstract][Full Text] [Related]
14. Analysis of the binding of fluorescent C5a and C3a to human peripheral blood leukocytes.
van Epps DE; Chenoweth DE
J Immunol; 1984 Jun; 132(6):2862-7. PubMed ID: 6373920
[TBL] [Abstract][Full Text] [Related]
15. C5a and C5a(desArg) enhance the susceptibility of monocyte-derived macrophages to HIV infection.
Kacani L; Bánki Z; Zwirner J; Schennach H; Bajtay Z; Erdei A; Stoiber H; Dierich MP
J Immunol; 2001 Mar; 166(5):3410-5. PubMed ID: 11207298
[TBL] [Abstract][Full Text] [Related]
16. Complement inhibition in ANCA vasculitis.
Jayne D
Nephrol Ther; 2019 Nov; 15(6):409-412. PubMed ID: 31631015
[TBL] [Abstract][Full Text] [Related]
17. C3a activates reactive oxygen radical species production and intracellular calcium transients in human eosinophils.
Elsner J; Oppermann M; Czech W; Dobos G; Schöpf E; Norgauer J; Kapp A
Eur J Immunol; 1994 Mar; 24(3):518-22. PubMed ID: 8125125
[TBL] [Abstract][Full Text] [Related]
18. A comparison of C3a and C5a-mediated stable adhesion of rolling eosinophils in postcapillary venules and transendothelial migration in vitro and in vivo.
DiScipio RG; Daffern PJ; Jagels MA; Broide DH; Sriramarao P
J Immunol; 1999 Jan; 162(2):1127-36. PubMed ID: 9916743
[TBL] [Abstract][Full Text] [Related]
19. New concepts on the therapeutic control of complement anaphylatoxin receptors.
Hawksworth OA; Li XX; Coulthard LG; Wolvetang EJ; Woodruff TM
Mol Immunol; 2017 Sep; 89():36-43. PubMed ID: 28576324
[TBL] [Abstract][Full Text] [Related]
20. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
